Table 1 Patient characteristics and univariate analysis
Characteristics | Patient number | Training Cohort (512 samples) | Testing Cohort (986 samples) | ||||
|---|---|---|---|---|---|---|---|
749 (100) | Necrosis (+) | Necrosis (−) | P | Necrosis (+) | Necrosis (−) | P | |
Age, mean ± SD, years | 48.7 ± 12.0 | 48.8 ± 9.36 | 47.4 ± 11.7 | .453 | 50.3 ± 10.6 | 49.2 ± 12.3 | .595 |
Gender | .528 | .131 | |||||
Male | 504 (67.3) | 29 (5.6) | 369 (72.1) | 27 (2.7) | 683 (69.3) | ||
Female | 195 (26.0) | 11 (2.1) | 103 (20.1) | 12 (1.2) | 264 (26.8) | ||
Diabetes | .526 | .551 | |||||
Yes | 41 (5.5) | 3 (0.6) | 19 (3.7) | 1 (0.1) | 59 (6.0) | ||
No | 708 (94.5) | 37 (7.2) | 453 (88.5) | 38 (3.9) | 888 (90.1) | ||
Hypertension | 1.000 | .131 | |||||
Yes | 79 (10.6) | 4 (0.8) | 42 (8.2) | 1 (0.1) | 111 (11.3) | ||
No | 670 (89.5) | 36 (7.0) | 430 (84.0) | 38 (3.9%) | 836 (84.8) | ||
T-stage | .045* | .002* | |||||
T1 | 215 (28.7) | 5 (1.0) | 119 (23.2) | 5 (0.5) | 301 (30.5) | ||
T2 | 244 (32.6) | 16 (3.1) | 172 (33.6) | 9 (0.9) | 291 (29.5) | ||
T3 | 194 (25.9) | 7 (1.3) | 89 (17.4) | 19 (1.9) | 263 (26.7) | ||
T4 | 96 (12.8) | 12 (2.3) | 82 (16.0) | 6 (0.6) | 92 (9.3) | ||
N-stage | .421 | .155 | |||||
N0 | 109 (14.5) | 4 (0.8) | 74 (14.4) | 4 (0.4) | 136 (13.8) | ||
N1 | 332 (44.3) | 24 (4.7) | 192 (37.5) | 24 (2.4) | 424 (43.0) | ||
N2 | 216 (28.8) | 10 (2.0) | 168 (32.8) | 10 (1.0) | 244 (24.7) | ||
N3 | 92 (12.28) | 2 (0.4) | 38 (7.4) | 1 (0.1) | 143 (14.5) | ||
Overall stage | .913 | .763 | |||||
I | 45 (6.01) | 1 (0.2) | 25 (4.9) | 0 (0) | 64 (6.5) | ||
II | 226 (30.2) | 17 (3.3) | 133 (26.0) | 8 (0.8) | 294 (29.8 | ||
III | 295 (39.4) | 8 (1.6) | 196 (38.3) | 24 (2.4) | 362 (36.7) | ||
IVA | 91 (12.15) | 12 (2.3) | 80 (15.6) | 6 (0.6) | 84 (8.5) | ||
IVB | 92 (12.3) | 2 (0.4) | 38 (7.4) | 1 (0.1) | 143 (14.5) | ||
Induction chemotherapy | .477 | .832 | |||||
Yes | 550 (73.4) | 30 (5.9) | 322 (62.9) | 12 (1.2) | 264 (26.8) | ||
No | 194 (25.9) | 10 (2.0) | 150 (29.3) | 27 (2.7) | 683 (69.3) | ||
Concurrent chemotherapy | 1.000 | .080 | |||||
Yes | 334 (44.6) | 20 (3.9) | 242 (47.3) | 35 (3.5) | 723 (73.3) | ||
No | 415 (55.4) | 20 (3.9) | 230 (44.9) | 4 (0.4) | 224 (22.7) | ||
Adjuvant chemotherapy | .662 | .418 | |||||
Yes | 226 (30.2) | 11 (3.1) | 109 (21.3) | 19 (1.9) | 387 (39.2) | ||
No | 523 (69.8) | 29 (5.7) | 363 (70.9) | 20 (2.0) | 560 (56.8) | ||
Predicted probability, median (95% range) | 9.8 (5.0–19.1) | 6.7 (3.6–13.9) | <.001* | 8.4 (5.1–25.3) | 6.4 (3.1–15.4) | <.001* | |